Introduction
============

Posthemorrhagic hydrocephalus of prematurity (PHHP) is a severe form of acquired symptomatic hydrocephalus. PHHP, the combination of ventriculomegaly and elevated intracranial pressure, occurs most commonly in preterm infants who suffer severe intraventricular hemorrhage (IVH) during the first few days of life. Severe IVH is defined as germinal matrix hemorrhage distending a ventricle or involving adjacent parenchyma. Worldwide, ∼1.6 million early preterm infants (\<32 weeks gestation) are born annually ([@B11]). In countries with advanced medical care, 8--23% of these early preterm infants (∼300,000 infants per year) are afflicted by severe IVH ([@B4]; [@B94]; [@B100]; [@B93]). Symptomatic PHHP typically develops weeks after IVH, and represents the worst outcome along a spectrum of severity after severe IVH. The spectrum ranges from ventriculomegaly without signs of elevated intracranial pressure to symptomatic PHHP that requires an invasive intervention. Of surviving early preterm infants with severe IVH, 50--60% will exhibit ventriculomegaly on head ultrasound (HUS) during the newborn admission ([@B4]; [@B100]), 20--30% will develop symptomatic hydrocephalus that requires temporary treatment ([@B4]; [@B94]), and 16--20% will require permanent intervention ([@B4]; [@B94]; [@B100]). Currently, the only effective treatment for PHHP is surgical intervention ([@B74]), yet most infants and children throughout the world do not have access to safe, timely neurosurgical care ([@B81]). In the United States, pediatric hydrocephalus treatment consumes \$1.4--2 billion dollars annually (2003 dollars) ([@B109]). The most common neurosurgical intervention for PHHP, insertion of a permanent cerebrospinal fluid (CSF) shunt, brings lifelong dependence on devices prone to malfunction and infection. In a recent multi-center study in the United States, PHHP was the most common reason for initial shunt insertion, and one third of initial infant shunts failed with a mean time to failure of \<1 year ([@B96]). Shunt outcomes are much worse in regions without advanced neurosurgical care ([@B105]). Other surgical options for infants, such as endoscopic third ventriculostomy with choroid plexus coagulation (ETV-CPC), have not shown superior durability to shunts ([@B61]). The need for safe, effective, economical, non-surgical treatment of PHHP cannot be over-stated.

Over the past two decades, perinatal neuroreparative strategies have been translated into clinical trials ([@B55]; [@B67]; [@B87]; [@B124]; [@B57]) and practice ([@B35]). This progress motivated us to re-examine non-surgical treatment of PHHP. The pluripotent cytokines, erythropoietin (EPO) and melatonin (MLT), are leading candidates for neurorepair in neonates with central nervous system (CNS) injury due to their safety profile ([@B97]), and multiple and complementary, mechanisms of action on developing neural cells ([@B12]; [@B15]; [@B73]; [@B47]). Both EPO and MLT support the genesis, survival and maturation of neural cells ([@B46]; [@B73]; [@B52]; [@B68]; [@B132]), reduce excess calpain degradation ([@B104]; [@B49], [@B54]; [@B99]), limit neuroinflammation and oxidative damage ([@B14]; [@B95]; [@B24]; [@B77]; [@B120]; [@B122]; [@B135]), and suppress endoplasmic reticulum stress and mitochondrial dysfunction ([@B42]; [@B21]; [@B13]; [@B30]; [@B38]; [@B134]; [@B44]; [@B39]; [@B78]; [@B114]; [@B127]). Individually, EPO and MLT are in clinical trials to ameliorate CNS injury from extremely preterm birth, demonstrating their clinical viability as therapeutics in preterm infants ([@B56]; [@B87], [@B86]; [@B28]; [@B124]; [@B16]). A multi-pronged therapeutic approach is commonly used for other medical disorders that have multiple interacting targets, and may benefit PHHP ([@B36]).

The association of intrauterine inflammation, or chorioamnionitis (CAM), with IVH has been recognized around the world ([@B80]; [@B103]; [@B6]; [@B108]; [@B65]; [@B69]; [@B111]; [@B19]; [@B25]). In a recent study, 26.7% of early preterm infants with CAM exposure suffered IVH, compared to only 17.8% of infants without CAM exposure ([@B25]). Systemic inflammation is also implicated in the need for surgical intervention for PHHP ([@B4]). In a longitudinal study of early preterm infants, the incidence of IVH remained stable at 8% for over a decade ([@B4]). By contrast, the incidence of sepsis dropped significantly. Interestingly, the need for surgical intervention for PHHP declined and followed the sepsis trend, rather than remaining stable and trending with IVH ([@B4]). Decades ago, [@B102] described widespread ependymal changes after IVH visualized throughout the ventricular system on HUS. These changes were not restricted to areas of IVH, implicating a diffuse ependymal reaction after IVH. Together, these clinical studies suggest associations between prenatal systemic inflammation that impacts the developing CNS, an increased risk of IVH, diffuse ependymal reaction following IVH, and the greater need for surgical intervention to treat symptomatic hydrocephalus.

Recent advances in neuroscience have shed new insights on the pathogenesis of symptomatic hydrocephalus. Ependymal motile cilia (EMC) propel CSF through the ventricles ([@B9]; [@B106]; [@B27]). Ependymal cells arise from radial glia in the third trimester ([@B110]), which in rodents is equivalent to approximately the first postnatal week ([@B107]; [@B53]). The genesis, maturation and anatomical arrangement of EMC is complex and strictly regulated during development, primarily from postnatal day 3 (P3) through 21 in rats ([@B9]; [@B37]; [@B79]; [@B115]; [@B64]; [@B23]; [@B63]; [@B29]; [@B113]; [@B1]; [@B20]; [@B70]). Development of EMC occurs precisely during the perinatal period when early preterm infants suffer associated CNS injury from CAM and IVH ([@B23]). After IVH in human preterm infants, ependymal cells lining the ventricles are replaced by astrocytic glial nodules in a process termed ventricular disruption ([@B31], [@B32]; [@B76]). Similarly, EMC injury occurs following intracerebral hematoma ([@B18]), traumatic brain injury (TBI) ([@B125]) and stroke ([@B129]). Converging lines of evidence suggest that damage to EMC leads to excessive accumulation of CSF and symptoms of elevated intracranial pressure.

We propose EMC failure leading to symptomatic hydrocephalus is precipitated by systemic inflammation in combination with a second CNS insult, such as hemorrhage or TBI. [@B131] demonstrated that fetal intraventricular lysophosphatidic acid (LPA), a blood-borne inflammatory signaling molecule, precipitates congenital hydrocephalus, and Park subsequently showed that LPA reduces yes-associated protein (YAP), and ependymal maturation ([@B91]). YAP drives the differentiation of radial glial cells toward ependymal cells ([@B91]). Without adequate YAP present, radial glial cells become astrocytes ([@B45]). We hypothesize that CAM plus early IVH induces symptomatic hydrocephalus that replicates human infant PHHP, and that this occurs in part through alteration of periventricular YAP. Moreover, we propose that combined treatment with EPO and MLT can prevent EMC damage, and thus PHHP. Herein, we report a novel, clinically relevant model of PHHP that combines prenatal injury to induce CNS inflammation plus early postnatal IVH, and prevention of PHHP with neonatal EPO+MLT treatment. This clinically viable, non-surgical intervention prevents acquired hydrocephalus in a preclinical model that exhibits macrocephaly, ventriculomegaly and developmental delay (poor cliff aversion performance), mimicking symptomatic PHHP in human infants.

Materials and Methods {#s1}
=====================

Study Design
------------

The primary study objective was to determine if progressive macrocephaly and ventriculomegaly could be reliably induced in neonatal rats using a combination of CAM and IVH, and if combinatorial therapy with EPO+MLT could prevent these two hallmarks of PHHP. For each experiment with a statistical analysis, a power analysis was performed to estimate the required sample size (G^∗^Power 3.1.9.3). We used preliminary and published data to estimate means and standard deviations for each group for the primary outcomes of intra-aural distance, ventriculomegaly, neurodevelopmental assessment, qPCR, and DTI analyses ([@B26]; [@B131]; [@B7]; [@B48],[@B49], [@B47]; [@B99]). Scanning electron microscopy qualitative analysis of EMC was set *a priori* as two per group. Primary endpoints were set *a priori* as described in the text, and were daily (P4-P15 and P21) for IAD and neurodevelopment, P5 for ventriculomegaly, P15 for periventricular YAP mRNA, and P21 for remaining assays. No animals were individually excluded except, as noted in the text, those who were removed prior to P21 due to poor health. DTI images from one rat were excluded due to poor image acquisition quality prior to quantification. Rats from both institutions and at least two separate litters were used for all experiments, except rats for SEM were prepared at one institution. Rats from both sexes were randomly assigned to injury (CAM versus sham at E18, IVH versus vehicle at P1) and to treatment group (EPO+MLT or vehicle on P2 for CAM-IVH rats). Each rat pup was coded to ensure all observations and assays and data analyses were performed blinded prior to decoding for interpretation.

Animals
-------

All procedures followed the National Research Council guidelines, and were performed with the approval of IACUCs at Johns Hopkins University (RA16M369) and the University of New Mexico Health Sciences Center (16-200398-HSC). Timed pregnant Sprague-Dawley dams were purchased (Charles River). Rats had *ad libitum* food and water, and a standard 12-h light dark cycle. Pups were raised with dams and weaned at P21. Pups were monitored daily for weight and other signs of health. A total of 298 pups were used for this study. Both sexes, and rats from at least two separate litters were used for all experiments. The experimental paradigm is presented in **Figure [1A](#F1){ref-type="fig"}**. ARRIVE guidelines were followed ([@B59]). An initial cohort of 135 rat pups \[43 sham-vehicle (sterile saline), 35 sham-IVH, 27 CAM-vehicle, and 30 CAM-IVH\] was used to establish the model of PHHP. A second cohort of 89 rats (31 sham-veh rats, 35 CAM-IVH vehicle-treated rats, and 23 CAM-IVH EPO+MLT-treated rats) was used to test if treatment begun on P2 could prevent the development of PHHP. A third cohort of 74 pups (10 naïve vehicle-treated rats, 20 naïve EPO+MLT-treated rats, 13 vehicle-treated CAM-vehicle rats, 8 vehicle-treated CAM-IVH rats, 5 MLT-treated CAM-IVH rats, 9 EPO-treated CAM-IVH rats, and 9 EPO+MLT-treated CAM-IVH rats) was used for additional control experiments. Whenever possible, each pup was used for multiple assays.

![Prenatal chorioamnionitis (CAM) plus postnatal day 1 (P1) intraventricular injection of lysed red blood cells (IVH), or CAM-IVH, causes progressive macrocephaly, ventriculomegaly and neurodevelopmental delay. **(A)** Experimental paradigm. **(B)** Coronal head ultrasound on P2 demonstrating bilateral IVH. **(C)** A representative P7 rat with CAM-IVH exhibits a domed cranial vault, while a sham-IVH rat does not. **(D)** CAM-IVH rats show a disproportionate increase in intra-aural distance (IAD), a surrogate for head circumference, while control rats (sham-veh, sham-IVH and CAM-veh) do not. **(E)** Hematoxylin and eosin staining of coronal sections of the lateral ventricle at P5 demonstrate ventriculomegaly in CAM-IVH rats. Bar = 500 microns. **(F)** Ventricular volume measured with unbiased stereology of HE sections at P5 is mildly increased in CAM-veh rats, and markedly elevated in CAM-IVH rats, compared to sham-veh or sham-IVH rats. **(G)** Ventricular volume quantified from coronal *ex vivo* T2 MRI slices shows that ventriculomegaly in CAM-IVH rats is sustained through P21, compared to sham-veh, sham-IVH and CAM-veh rats. **(H)** Both CAM-veh and CAM-IVH rats exhibit delayed performance on cliff aversion, a neonatal neurodevelopmental test. (**D** is mixed model repeated measures ANOVA with Bonferroni's correction and all other comparisons are two-way ANOVA with Bonferroni's correction, ^∗^*p* \< 0.05, ^∗∗^*p* ≤ 0.01, ^∗∗∗^*p* ≤ 0.001.)](fncel-12-00322-g001){#F1}

Chorioamnionitis (CAM) on Embryonic Day 18
------------------------------------------

To induce CAM, under isoflurane anesthesia pregnant dams underwent laparotomy on embryonic day 18 (E18) with transient uterine artery occlusion for 60 min followed by intra-amniotic injection of lipopolysaccharide (LPS, 0111:B4, Sigma, St. Louis, MO, United States, 4 μl/sac) ([@B48], [@B51]; [@B72]). The laparotomy was closed and pups were born on E22. Shams underwent anesthesia and laparotomy for 60 min without uterine artery occlusion or LPS injection. 44 dams underwent laparotomy to generate the animals for this study.

Intraventricular Injection on Postnatal Day 1
---------------------------------------------

For litters with IVH injection, one pup from each litter was randomly chosen as a donor for syngeneic lysed red blood cells (RBCs). Lysed RBCs were chosen because of prior work that suggested lysed RBCs best replicate human IVH ([@B112]; [@B34]). Donor blood was collected, centrifuged at 500 ×*g* for 10 min, washed three times with sterile PBS (phosphate-buffered saline), and then lysed with a standardized series of freeze-thaw cycles. On postnatal day 1 (P1), CAM or sham pups were randomly assigned to injection of lysed RBCs (IVH) or vehicle (sterile saline, pH 7.4). The mean hematocrit of P1 lysed RBCs was 37.2 ± 0.9% for shams (*n* = 3) and 36.9 ± 0.6% for CAM rats (*n* = 3). Using hypothermia for sedation, transillumination, and standard landmarks for the lateral ventricle (0.2 mm anterior to the coronal suture and 1 mm lateral of midline), either vehicle or lysed RBCs (20 μl) was injected into each lateral ventricle using a micro-syringe with a 31 gauge needle ([@B60]; [@B82]). Lysed RBCs or vehicle was slowly infused freehand with a percutaneous needle, as previously reported, because neonatal rats at P1 cannot be placed in a stereotactic frame ([@B82]). Placement was confirmed visually with transillumination. After 15--20 s the needle was removed, and pups were rewarmed and returned to their dams. Rats were coded and labeled to blind observers for subsequent assessments. Ultrasound (VScan Extend Dual Probe, GE Healthcare) was used to confirm IVH on P2.

Extended Erythropoietin (EPO) Plus Melatonin (MLT) Treatment
------------------------------------------------------------

To test if EPO+MLT could prevent the onset of PHHP, on P2 CAM+IVH rats were randomized to receive either EPO+MLT or vehicle from P2 (equivalent to approximately 32 weeks human gestation) to P10 (full term in humans). Six doses of EPO (2500 U/kg/dose i.p.) or vehicle were administered on P2-P5, P7 and P9. Nine doses of MLT (20 mg/kg/dose i.p.) or vehicle were administered on P2-P10. A subset of 36 CAM-IVH pups were randomized to receive vehicle, EPO alone, MLT alone, or EPO+MLT to test impact of treatment on macrocephaly. Shams did not receive EPO+MLT because both EPO and MLT have previously been shown to be safe in these dosing regimens as individual agents ([@B56]; [@B73]; [@B87]; [@B28]; [@B16]). To determine if EPO+MLT had any unanticipated effect on normal neurodevelopment, a set of naïve pups underwent EPO+MLT treatment. Doses were administered the same time of day to minimize any impact of MLT on the circadian rhythm, although no impact was evident.

Intra-Aural Distance (IAD)
--------------------------

Observers blinded to injury and treatment group measured 200 rats (cohort 1 = 87, cohort 2 = 69, and cohort 3 = 44). Daily measurements included IAD ([@B131]) and body weight for dosing calculations.

Neurodevelopmental Assessment
-----------------------------

Neurodevelopmental battery included nine tests (surface righting, negative geotaxis, cliff aversion, forelimb grasp, audio startle, eye opening, ear twitch, forelimb placement, and air righting) ([@B26]; [@B7]). Since no differences with audio startle or eye opening were noted across groups, these two tests were not included for naïve rats. Observers blinded to injury and treatment group tested 146 rats each day from P4 to P15, and then at P21.

Histology
---------

Animals were anesthetized and perfused with PBS and then 4% paraformaldehyde (PFA), and brains were collected. After immersion in 30% sucrose, coronal frozen sections were cut on a cryostat. Hematoxylin and eosin (HE) staining, immunohistochemistry (IHC) and unbiased stereology were performed, as previously published ([@B48]). Sections stained with HE were used for ventricular volume. For IHC, briefly, sections were washed and then incubated sequentially with 0.3% hydrogen peroxide and blocking solution containing 10% goat serum in PBS. Primary GFAP antibodies (Dako 1:500, Carpinteria, CA, United States) in blocking solution containing 0.1% Triton were incubated on sections overnight at 4°C. The next morning, sections were rinsed, incubated with species-appropriate biotinylated secondary antibodies, followed by Vectastain (Vector Labs, Burlingame, CA, United States) and 3′3′-diaminobenzidine (DAB). Sections were dehydrated, cleared in xylenes and cover-slipped with Permount (Millipore Sigma, St. Louis, MO, United States). Although dehydration can affect ventricular volume measurements in slide mounted sections, all sections were dehydrated equally, including equivalent times in graded ethanol solutions and xylenes. Appropriate negative controls (no primary antibodies) were run in parallel. Using bright-field illumination, representative images were photographed on a Leica microscope. Observers blinded to injury and treatment status quantified ventricular volumes with Stereologer software (Stereology Resource Center, Tampa, FL, United States) on an upright Leica microscope using optical fractionator methodology under the 40× objective.

Quantitative PCR
----------------

Quantitative PCR was performed as previously published ([@B48]). Primers for YAP were obtained from the literature ([@B45]), and verified with BLAST (National Center for Biotechnology Information Nucleotide Basic Local Alignment Search Tool). Briefly, ependyma at P15 were rapidly dissected for RNA isolation (RNeasy Mini kit; Qiagen, Germantown). Following extraction, RNA was transcribed to cDNA, followed by RT-PCR using SYBR green and YAP primers. Experimental replicates were run in triplicate and those CT values varying by more than 0.25 standard deviations were excluded from all analyses. Pooled adult naïve cortex was used to standardize across plates.

MRI for Ventricular Volume and Microstructural Integrity
--------------------------------------------------------

*Ex vivo* MRI T2 and diffusion tensor imaging (DTI) images were acquired at P21 on 33 rats using a Bruker Biospec 7T 70/30 Ultra Shield Refrigerated (USR) nuclear MRI system. Briefly, rats were anesthetized and perfused with PBS, followed by 4% PFA. Brains were post-fixed in 4% PFA for 1 week and embedded in 2% agarose containing 3 mM sodium azide. A T2 multi-slice multi-echo (MSME) sequence was performed with a TR of 3000 ms and TE of 12 ms. FOV was 3 cm × 3 cm, with a slice thickness of 1 mm, 12 slices total, and matrix of 256 × 256, as previously published ([@B50]; [@B99]). Echo-planar diffusion tensor imaging (EP-DTI) images of twelve contiguous coronal 1 mm slices was obtained with a FOV of 3. Ventricular volume was calculated from manually traced regions of interest (ROI) by observers blinded to injury and treatment status. Areas within each slice were calculated, summed across slices and multiplied by slice thickness. DTI was quantified for ROI consistent with previous publications ([@B50]; [@B99]). Because the intraventricular injections were performed bilaterally, for bilateral structures the metrics were acquired on each side and averaged per ROI for each rat.

Scanning Electron Microscopy (SEM)
----------------------------------

Six rats on P21 were perfused with PBS, followed by a mixture of 2.5% glutaraldehyde/2% PFA/0.1 M sodium cacodylate/HCl buffer pH 7.2. Anterior and posterior areas of the lateral or medial walls of the lateral ventricles were micro-dissected and fixed overnight. Anatomically matched tissues were incubated in 1% osmium tetroxide in 0.1 sodium cacodylate/HCl buffer for 4 h, dehydrated in a series of graded ethanol solutions, carbon-coated, then imaged in a Zeiss Sigma 300 field emission scanning electron microscope, consistent with published reports ([@B106]; [@B125]).

Quantification and Statistical Analysis
---------------------------------------

In all studies, each rat represents true n. Observers were blinded to injury and treatment status for all data acquisition and initial analyses. For all data sets normal distribution was verified with the Shapiro--Wilk test, with Levene's test to confirm homogeneity of variances. For comparisons of multiple groups that were normal in distribution, two-way ANOVA with Bonferroni's correction was performed (SPSS 24, IBM). For comparison of IADs across groups and ages, a mixed model repeated measures ANOVA with Bonferroni correction was used. For comparison of non-parametric values (categories of ventricular volume), Wilcoxon rank sum test was performed. A Type I error of *p* \< 0.05 was considered significant. Mean diffusivity ellipsoids were graphed with MATLAB, R2017b.

Results
=======

This model incorporates prenatal CNS injury from CAM, early postnatal IVH with syngeneic lysed RBCs, and neurological assessment for 3 weeks through P21 in rodents, a period with some CNS developmental equivalence in humans to early childhood (**Figure [1A](#F1){ref-type="fig"}**). An initial cohort of 135 pups of both sexes was used to characterize a model of PHHP \[43 sham-veh (sterile saline) intraventricular injection, 35 sham-IVH, 27 CAM-veh, and 30 CAM-IVH\]. Presence of IVH after injection was confirmed by HUS in a subset of pups (**Figure [1B](#F1){ref-type="fig"}**). Early mortality (\<48 h) did not differ between injection groups, and was 13% (18/135). No rats from the three control groups (sham-veh, sham-IVH and CAM-veh) became symptomatic from injections, while 4/24 (17%) of CAM-IVH rats that initially survived required euthanasia prior to their targeted endpoint due to progressive macrocephaly accompanied by lethargy and spastic movements. Ventriculomegaly was confirmed on post-mortem examination, and these animals were excluded from further analyses. Surviving rats (113) were collected on P5, P15, and P21.

CAM-IVH Rats Exhibited Progressive Macrocephaly and Ventriculomegaly
--------------------------------------------------------------------

In human infants, symptomatic PHHP is characterized by progressive macrocephaly with the head circumference crossing percentiles for corrected-age. By P7, CAM-IVH pups developed a dome-shaped cranium (**Figure [1C](#F1){ref-type="fig"}**). To track progressive macrocephaly, intra-aural distance (IAD) was measured daily as a surrogate for human head circumference. Beginning at P5, a significant, progressive increase in IADs was observed in CAM-IVH rats (*n* = 22) through P21, compared to sham-veh (*n* = 33, mixed model repeated measures with Bonferroni's correction, *p* \< 0.001), sham-IVH (*n* = 20, *p* \< 0.001) and CAM-veh rats (*n* = 19, *p* \< 0.001) (**Figure [1D](#F1){ref-type="fig"}**). Both sexes with CAM-IVH exhibited similar patterns of macrocephaly (**Supplementary Figures [S1A,B](#SM1){ref-type="supplementary-material"}**). Thus, after the combination of perinatal CAM-IVH, neonatal rats displayed progressive macrocephaly through P21, a key component of PHHP.

To quantify early changes in ventricular size, P5 HE-stained coronal sections were analyzed. Ventriculomegaly was observed in CAM-IVH rats (*n* = 9), but not in sham-veh (*n* = 8, two-way ANOVA with Bonferroni correction, *p* \< 0.001) or sham-IVH (*n* = 4, *p* = 0.003) rats (**Figures [1E,F](#F1){ref-type="fig"}**). Consistent with our prior work ([@B48]), CAM-veh rats (*n* = 5) showed moderate ventricular enlargement compared to shams, but smaller than CAM-IVH (all *p* \> 0.05). Notably, the sham-IVH and CAM-veh rats with mild ventriculomegaly did not exhibit the progressive macrocephaly that was present only in CAM-IVH rats. These results show prenatal CAM plus postnatal IVH causes early ventriculomegaly.

To clarify whether the ventriculomegaly observed at P5 was transient or sustained, ventricular volumes were analyzed at P21 using *ex vivo* MRI. Ventricular volumes from CAM-IVH rats (*n* = 8) were significantly larger than sham-veh (*n* = 5), sham-IVH rats (*n* = 4), and CAM-veh rats (*n* = 6, **Figure [1G](#F1){ref-type="fig"}**). Ventricular volume at P21 correlated with macrocephaly (Pearson correlation *r* = 0.338, *p* = 0.012, **Table [1](#T1){ref-type="table"}**). Together, IAD measurements and ventricular volumes from histology and MRI demonstrate that only the combination of prenatal CAM plus early postnatal IVH leads to progressive macrocephaly with persistent ventriculomegaly, characteristic of PHHP.

###### 

Pearson *r* correlation of phenotypic parameters with significant DTI scalars.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------
  Parameter                                                                      Cliff aversion           Ventricular volume                     
  ------------------------- ---- -------------------------- -------------------- ------------------------ -------------------- ----------------- ------------------
  Macrocephaly (P21 IAD)\                                                        0.281\                   ***p* = 0.040**      0.338\            ***p* = 0.012**\
  Cliff aversion                                                                 X                                             0.461             ***p* \< 0.001**

                                                                                                                                                 

  **DTI scalars**                **Macrocephaly P21 IAD**   **Cliff aversion**   **Ventricular volume**                                          

                                 **Pearson *r***            ***p*-value**        **Pearson *r***          ***p-*value**        **Pearson *r***   ***p-*value**

                                                                                                                                                 

  White matter              FA   -0.585                     ***p* = 0.001**      -0.447                   ***p* = 0.012**      -0.376            ***p* = 0.040**

  Corpus callosum           FA   -0.427                     ***p* = 0.015**      -0.361                   ***p* = 0.006**      -0.325            *p* = 0.070

  Hippocampus               FA   -0.541                     ***p* = 0.001**      -0.247                   *p* = 0.181          -0.099            *p* = 0.591

  Striatum                  FA   -0.318                     *p* = 0.076          -0.444                   ***p* = 0.012**      -0.205            *p* = 0.261

  Thalamus                  FA   -0.201                     *p* = 0.270          -0.320                   *p* = 0.079          -0.210            *p* = 0.249

  White matter              MD   0.422                      ***p* = 0.016**      0.320                    *p* = 0.079          0.291             *p* = 0.106

  Corpus callosum           MD   0.467                      ***p* = 0.007**      0.382                    ***p* = 0.034**      0.383             ***p* = 0.030**

  White matter              RD   0.435                      ***p* = 0.013**      0.385                    ***p* = 0.033**      0.619             ***p* \< 0.000**

  Corpus callosum           RD   0.552                      ***p* = 0.001**      0.350                    ***p* = 0.006**      0.445             ***p* = 0.011**
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------

Bolded values indicate statistical significance.

Cumulative Insults Precipitated Developmental Delay
---------------------------------------------------

To assess neonatal neurodevelopment, a battery of age-appropriate, validated, functional tests ([@B26]; [@B7]) was administered. Most responses, including somatic reflexes such as eye opening and startle response, did not vary amongst the four groups (**Supplementary Figure [S2](#SM2){ref-type="supplementary-material"}**). The forelimb placement reflex, the placement of the forelimb on a shelf in response to stroking the dorsum of the forelimb while the rat is suspended near the shelf, was worse in CAM-veh and CAM-IVH rats compared to sham-veh rats (**Supplementary Figure [S2G](#SM2){ref-type="supplementary-material"}**). Cliff aversion, the time it takes a pup placed with its head and forelimbs over a ledge to return to a safe position, was longer in injured rats, consistent with early developmental delay. Specifically, CAM-IVH rats (*n* = 24) exhibited longer cliff aversion times compared to sham-veh rats (*n* = 24, *p* = 0.002), and sham-IVH rats (*n* = 18, *p* \< 0.001, **Figure [1H](#F1){ref-type="fig"}**). The CAM-veh rats (*n* = 31) also showed impairment with cliff aversion, but did not differ significantly from sham-veh or CAM-IVH rats. The pattern of poor cliff aversion performance by CAM-IVH rats was more pronounced in male rats than female rats (**Supplementary Figures [S1E,F](#SM1){ref-type="supplementary-material"}**). Notably, cliff aversion performance correlated with macrocephaly (*r* = 0.281, *p* = 0.040), and more robustly with ventriculomegaly (*r* = 0.461, *p* \< 0.001, **Table [1](#T1){ref-type="table"}**), suggesting that in this model early functional outcomes are associated with macrocephaly and ventriculomegaly.

Correlation of Phenotype With Early CNS Insults
-----------------------------------------------

To estimate the relative contribution of early CNS insults to phenotypic parameters important for PHHP, correlations were tested between individual findings and types of CNS insults. Macrocephaly (P21 IAD) correlated only with the combination of CAM-IVH (*r* = 0.420, *p* = 0.010), and not with CAM or IVH in isolation (**Table [2](#T2){ref-type="table"}**). Similarly, ventriculomegaly correlated only with CAM-IVH (*r* = 0.765, *p* = 0.002), and not with CAM or IVH alone. Poor cliff aversion performance also correlated with CAM-IVH (*r* = 0.467, *p* = 0.004, **Table [2](#T2){ref-type="table"}**). Overall, only the combined CAM-IVH correlated robustly with macrocephaly, ventriculomegaly, and poor functional performance that are characteristic of PHHP.

###### 

Pearson *r* correlation of CNS insults with phenotypic parameters and significant DTI scalars.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical parameter       Chorioamnionitis          IVH                       Chorioamnionitis plus IVH (vehicle)^∗^       Chorioamnionitis plus IVH (EPO+MLT)^∗∗^
  ------------------------ ------------------------- ------------------------- -------------------------------------------- -----------------------------------------
  Macrocephaly (P21 IAM)   -0.103 *p* = 0.574        -0.192 *p* = 0.405        0.420 ***p* = 0.010**                        -0.599 ***p* \< 0.001**

  Cliff aversion           0.323 *p* = 0.062         -0.462 *p* = 0.015        0.467 ***p* = 0.004**                        -0.367 ***p* = 0.042**

  Ventricular volume       0.522 *p* = 0.100         -0.028 *p* = 0.943        0.765 ***p* = 0.002**                        -0.341 *p* = 0.056

                                                                                                                            

  **DTI scalar**           **Chorioamnionitis**      **IVH**                   **Chorioamnionitis plus IVH (vehicle)**^∗^   **Chorioamnionitis**\
                                                                                                                            **plus IVH (EPO+MLT)**^∗∗^

                           **Pearson *r p*-value**   **Pearson *r p-*value**   **Pearson *rp*-value**                       **Pearson *rp*-value**

                                                                                                                            

  White matter FA          -0.421 *p* = 0.197        -0.626 *p* = 0.071        -0.813 ***p* = 0.002**                       0.800 ***p* \< 0.001**

  Corpus callosum FA       -0.532 *p* = 0.092        -0.374 *p* = 0.322        -0.791 ***p* = 0.001**                       0.830 ***p* \< 0.001**

  Hippocampus FA           -0.266 *p* = 0.430        0.122 *p* = 0.773         -0.735 ***p* = 0.004**                       0743 ***p* = 0.001**

  Striatum FA              -0.411 *p* = 0.209        -0.663 *p* = 0.052        -0.641 ***p* = 0.018**                       0.801 ***p* \< 0.001**

  Thalamus FA              -0.637 ***p* = 0.035**    0.244 *p* = 0.527         -0.640 ***p* = 0.019**                       0.896 ***p* = 0.012**

  White matter MD          0.261 *p* = 0.437         0.176 *p* = 0.651         0.792 ***p* = 0.001**                        -0.260 *p* = 0.313

  Corpus callosum MD       0.356 *p* = 0.282         0.046 *p* = 0.927         0.836 ***p* \< 0.001**                       -0.670 ***p* = 0.003**

  White matter RD          0.391 *p* = 0.234         0.392 *p* = 0.296         0.874 ***p* \< 0.001**                       -0.347 *p* = 0.173

  Corpus callosum RD       0.268 *p* = 0.425         0.036 *p* = 0.927         0.863 ***p* \< 0.001**                       -0.876 ***p* \< 0.001**
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

Bolded values indicate statistical significance.

∗

Chorioamnionitis, IVH and CAM-IVH rat correlations compared with sham-veh rats.

∗∗

EPO+MLT-treated CAM-IVH rats compared with vehicle-treated CAM-IVH rats.

EPO+MLT Prevented Macrocephaly and Neurodevelopmental Delay in PHHP-Like Rats
-----------------------------------------------------------------------------

To determine if the progressive macrocephaly and poor cliff aversion performance observed in CAM-IVH rats was preventable, we assessed the efficacy of combined EPO+MLT treatment in the neonatal period in a separate cohort of rats (*n* = 88). Specifically, on P2, CAM-IVH rats were randomized to an extended regimen of EPO+MLT or vehicle from P2 to P10. To determine whether the combination of EPO+MLT had any unanticipated impact on neurodevelopment, naïve rats were randomized to the same EPO+MLT regimen (*n* = 20), or vehicle (*n* = 10). No differences in neurodevelopment were detected (**Supplementary Figure [S3](#SM3){ref-type="supplementary-material"}**), consistent with prior studies showing no detrimental effects of EPO or MLT in shams ([@B73]; [@B13], [@B14]). Thus, shams received only vehicle for the remainder of the studies. While vehicle-treated CAM-IVH rats exhibited a domed head, EPO+MLT-treated CAM-IVH rats did not (**Figure [2A](#F2){ref-type="fig"}**). At P5, the IADs of the EPO+MLT-treated CAM-IVH rats (*n* = 15) were significantly lower than IADs of the vehicle-treated CAM-IVH rats (*n* = 28, mixed model repeated measures with Bonferroni correction, *p* = 0.017, **Figure [2B](#F2){ref-type="fig"}**). By P21, the IADs of the EPO+MLT-treated rats remained similar to shams (*n* = 28), and were markedly less than the vehicle-treated CAM-IVH rats (*p* \< 0.001). By contrast, when EPO alone (*n* = 9), or MLT alone (*n* = 5) were administered to CAM-IVH rats, the IADs were not significantly different compared littermates that received vehicle (*n* = 8, **Supplementary Figure [S1I](#SM1){ref-type="supplementary-material"}**). The EPO+MLT treatment prevented progressive macrocephaly in both male and female rats (**Supplementary Figures [S1C,D](#SM1){ref-type="supplementary-material"}**). In addition to preventing macrocephaly, neonatal EPO+MLT treatment also mitigated poor performance on cliff aversion after CAM-IVH. Compared to vehicle-treated CAM-IVH rats (*n* = 24), EPO+MLT-treated CAM-IVH rats (*n* = 17) exhibited shorter cliff aversion times (*p* = 0.026), and performed similar to shams (*n* = 24, **Figure [2C](#F2){ref-type="fig"}**). None of the other reflexes were significantly impacted by EPO+MLT, although a trend for surface righting was apparent (**Supplementary Figure [S2](#SM2){ref-type="supplementary-material"}**). While CAM-IVH rats of both sexes showed a similar pattern of improved cliff aversion performance with neonatal EPO+MLT treatment, the differences were more prominent in males (**Supplementary Figures [S1G,H](#SM1){ref-type="supplementary-material"}**). Thus, neonatal EPO+MLT treatment prevented progressive macrocephaly and early signs of developmental delay exhibited by vehicle-treated CAM-IVH rats.

![Extended neonatal treatment with erythropoietin (EPO) plus melatonin (MLT) prevents progressive macrocephaly and neurodevelopmental delay, and reduces sustained ventriculomegaly in CAM-IVH rats. **(A)** At P16, a vehicle-treated CAM-IVH rat exhibits a domed cranial vault, while the EPO+MLT-treated CAM-IVH rat does not. **(B)** IADs of EPO+MLT-treated CAM-IVH rats diverge from those of vehicle-treated CAM-IVH rats, and become similar to sham-veh rats. **(C)** EPO+MLT treatment of CAM-IVH rats prevents delayed performance on cliff aversion, compared to vehicle-treated CAM-IVH rats. **(D)** Ventricular volume measured on MRI at P21 was defined as normal, and mild, moderate and severe ventriculomegaly. Sham-veh and sham-IVH rats all had normal size ventricles, while all vehicle-treated CAM-IVH rats had ventriculomegaly. After neonatal EPO+MLT treatment, 40% of CAM-IVH rats had normal size ventricles, and the proportion with more severe ventriculomegaly shifted to less severe. Importantly, none of the EPO+MLT CAM-IVH rats with residual ventriculomegaly had macrocephaly. (**B**: a mixed model repeated measures ANOVA with Bonferroni's correction; **C**: two-way ANOVA with Bonferroni's correction; **D**: Wilcoxon rank sum test, ^∗^*p* \< 0.05, ^∗∗^*p* ≤ 0.01, ^∗∗∗^*p* ≤ 0.001.)](fncel-12-00322-g002){#F2}

EPO+MLT Treatment Improved Ventriculomegaly in PHHP-Like Rats
-------------------------------------------------------------

To determine if EPO+MLT treatment impacted ventriculomegaly, we evaluated ventricular volume at P21. Ventricular volume from *ex vivo* MRI was classified *a priori* as normal (\<10 mm^3^), mild (10--\<15 mm^3^), moderate (15--25 mm^3^) or severe (\>25 mm^3^) ventriculomegaly (**Figure [2D](#F2){ref-type="fig"}**). All of the sham-veh (5/5) and sham-IVH (4/4) rats had normal ventricular volume. Two-thirds (4/6) of CAM-veh rats exhibited a normal volume, while one-third had mild or moderate ventriculomegaly without macrocephaly, consistent with posthemorrhagic ventricular dilation observed in some toddlers born preterm with CNS injury ([@B90]). All (9/9) of the vehicle-treated CAM-IVH rats showed ventriculomegaly (33% mild, 22% moderate, and 44% severe). By contrast, 44% (4/9) of EPO+MLT-treated rats had a normal ventricular volume and only 11% had severe ventriculomegaly, a significant reduction in the proportion with ventriculomegaly compared to vehicle-treated CAM-IVH rats (Wilcoxon rank sum test, *p* = 0.005). The reduction of ventriculomegaly combined with the lack of macrocephaly suggests that PHHP occurs along a spectrum of severity that can be modulated with a timely neuroreparative intervention.

Microstructural Abnormalities Improved With EPO+MLT Treatment
-------------------------------------------------------------

Due to the challenges in obtaining reliable functional outcomes in neonates, DTI has emerged as an imaging biomarker for perinatal brain injury ([@B118]; [@B40]; [@B88]). In particular, congenital hydrocephalus in children is associated with widespread DTI microstructural abnormalities ([@B71]; [@B133]). To supplement the functional outcome quantified with the behavior battery, we assessed regional variation in white and gray matter microstructure (**Figures [3](#F3){ref-type="fig"}**, **[4A](#F4){ref-type="fig"}**). Vehicle-treated CAM-IVH rats (*n* = 8) had markedly lower external capsule white matter (ECWM) fractional anisotropy (FA) at P21 compared to shams (*n* = 5, two-way ANOVA with Bonferroni's correction *p* \< 0.001), that improved with EPO+MLT (*n* = 9, *p* = 0.001, **Figure [4B](#F4){ref-type="fig"}**) A similar pattern with FA was observed in the central corpus callosum (shams versus vehicle-treated CAM-IVH, *p* = 0.002; vehicle-treated versus EPO+MLT-treated CAM-IVH, *p* \< 0.001, **Figure [4C](#F4){ref-type="fig"}**). Likewise, gray matter FA was lower in vehicle-treated CAM-IVH rats compared to shams in the hippocampus (*p* = 0.022, **Figure [4D](#F4){ref-type="fig"}**), striatum (*p* = 0.028, **Figure [4E](#F4){ref-type="fig"}**) and thalamus (*p* = 0.030, **Figure [4F](#F4){ref-type="fig"}**). Significantly, neonatal EPO+MLT treatment in CAM-IVH rats prevented loss of gray matter microstructural integrity in hippocampus (*p* \< 0.001), striatum (*p* \< 0.001), and thalamus (*p* = 0.018). Thus, while CAM-IVH causes extensive loss of microstructural integrity by P21, neonatal EPO+MLT treatment prevents this widespread damage.

![Coronal T2 images demonstrate ventricular size. Directionally encoded color maps of coronal images reveal widespread white and gray matter microstructural abnormalities in vehicle-treated CAM-IVH rats that are prevented by neonatal EPO+MLT treatment. Color maps show loss of microstructural coherence and impaired directional diffusion in regions with poor microstructural integrity. Directional colors are red for transverse, green for vertical and blue for orthogonal to the plane.](fncel-12-00322-g003){#F3}

![Diffusion tensor imaging (DTI) regional analyses and fractional anisotropy (FA) graphs quantify prevention of loss of microstructural integrity. **(A)** Diagram of DTI regions of interest (purple -- striatum, yellow -- corpus callosum, pink -- external capsule white matter (ECWM), green -- thalamus, and maroon -- hippocampus). **(B)** Reduction of FA in the ECWM of vehicle-treated CAM-IVH rats is prevented in CAM-IVH rats with neonatal EPO+MLT treatment. **(C)** Similarly, reduction of FA in the central corpus callosum of vehicle-treated CAM-IVH rats is prevented by EPO+MLT treatment. **(D)** FA in the hippocampus is also decreased in vehicle-treated CAM-IVH rats compared to shams, and EPO+MLT treatment mitigates the damage. **(E)** Likewise, FA in the striatum is reduced in vehicle-treated CAM-IVH rats, and prevented in EPO+MLT-treated CAM-IVH rats. **(F)** FA in the thalamus is also lower in vehicle-treated CAM-IVH rats compared to shams, and normalizes with EPO+MLT treatment (all comparisons are two-way ANOVA with Bonferroni's correction, ^∗^*p* \< 0.05, ^∗∗^*p* ≤ 0.01, ^∗∗∗^*p* ≤ 0.001).](fncel-12-00322-g004){#F4}

To more specifically examine microstructural integrity in the corpus callosum and ECWM, we assessed directional diffusion. Mean diffusivity (MD) was elevated in the corpus callosum of vehicle-treated CAM-IVH rats compared to shams (*p* = 0.001) and EPO+MLT-treated CAM-IVH rats (*p* = 0.008, **Figures [5A,B](#F5){ref-type="fig"}**). Axial diffusivity was not altered in the corpus callosum of CAM-IVH rats (**Figure [5C](#F5){ref-type="fig"}**). By contrast, radial diffusivity (RD), a potential imaging biomarker of myelin injury, was also elevated in the corpus callosum of vehicle-treated CAM-IVH rats, compared to shams and EPO+MLT-treated CAM-IVH rats (both *p* \< 0.001, **Figure [5D](#F5){ref-type="fig"}**). Similarly, ECWM RD was elevated in vehicle-treated CAM-IVH rats, compared to shams (*p* = 0.001) and EPO+MLT-treated CAM-IVH rats (*p* = 0.027, **Figure [5E](#F5){ref-type="fig"}**). Together, these findings show that the corpus callosum and ECWM are particularly vulnerable to CAM-IVH, and that early EPO+MLT treatment can prevent microstructural abnormalities caused by prenatal CAM plus IVH.

![Directional diffusivity in central corpus callosum and external capsule white matter is altered by CAM-IVH and EPO+MLT treatment. **(A)** Mean diffusivity is elevated in the corpus callosum vehicle-treated CAM-IVH rats, compared to shams and EPO+MLT-treated CAM-IVH rats. **(B)** Ellipsoids comprised of the three major eigenvectors of diffusion in the central corpus callosum illustrate the changes in vehicle-treated and EPO+MLT-treated CAM-IVH rats. **(C)** Axial diffusivity is relatively unaffected by CAM-IVH. **(D)** Vehicle-treated CAM-IVH rats exhibit elevated radial diffusivity (RD) in central corpus callosum, and neonatal EPO+MLT treatment normalizes the microstructural integrity. **(E)** Similarly, vehicle-treated CAM-IVH rats show increased RD in the ECWM, and neonatal EPO+MLT treatment normalizes the RD (all comparisons are two-way ANOVA with Bonferroni's correction, ^∗^*p* \< 0.05, ^∗∗^*p* ≤ 0.01, ^∗∗∗^*p* ≤ 0.001).](fncel-12-00322-g005){#F5}

We tested correlations of DTI scalars with macrocephaly, impaired cliff aversion performance, and ventriculomegaly (**Table [1](#T1){ref-type="table"}**). Macrocephaly (P21 IAD) correlated robustly with FA in the ECWM (*p* = 0.001), corpus callosum (*p* = 0.015) and hippocampus (*p* = 0.001). Similarly, poor cliff aversion performance correlated strongly with FA in the ECWM (*p* = 0.012), corpus callosum (*p* = 0.006), and striatum (*p* = 0.012), while ventriculomegaly correlated with corpus callosum FA (*p* = 0.04). For mean diffusivity, all three phenotypic metrics (macrocephaly, poor cliff aversion performance, and ventriculomegaly) showed strong correlation with corpus callosum MD (all *p* \< 0.03, **Table [1](#T1){ref-type="table"}**), while only macrocephaly was associated with altered ECWM MD (*p* = 0.016). Moreover, for radial diffusivity, all three phenotypic metrics showed strong correlation with both corpus callosum and ECWM RD (all *p* \< 0.035, **Table [1](#T1){ref-type="table"}**). Together, these finding show DTI scalars, particularly RD of white matter, are indicative of phenotypic parameters that most closely resemble PHHP, and suggest that metrics of directional diffusion may serve as biomarkers of PHHP severity and recovery.

Next, to test the impact of different components of CNS injury on DTI scalars, we examined the correlations between CAM, IVH, and CAM-IVH compared to shams. Only thalamic FA correlated with CAM alone (*p* = 0.035), and only striatal FA showed a trend with IVH alone (*p* = 0.052, **Table [2](#T2){ref-type="table"}**). By contrast, FA from both white and gray matter correlated with CAM-IVH (all *p* \< 0.02). Moreover, for both ECWM and corpus callosum, both MD and RD showed very robust correlations with CAM-IVH (all *p* ≤ 0.001). Finally, the correlations between DTI scalars for vehicle-treated compared to EPO+MLT-treated CAM-IVH rats were analyzed. These also showed strong correlations with DTI scalars when compared with vehicle-treated CAM-IVH rats (**Table [2](#T2){ref-type="table"}**). Thus, in addition to DTI correlating with phenotypic parameters, DTI scalars may hold promise as imaging biomarkers for specific CNS insults associated with PHHP, and neurorepair.

EPO+MLT Treatment Ameliorated Morphological Damage to Ependymal Motile Cilia
----------------------------------------------------------------------------

To examine EMC morphology, scanning electron microscopy (SEM) was performed on anatomically matched micro-dissected portions of the lateral ventricular wall on P21. Cilia from sham rats appeared in organized tufts (**Figure [6](#F6){ref-type="fig"}**). By contrast, a subset of cilia from vehicle-treated CAM-IVH rats were missing, while the remaining cilia were matted, flattened, and lacked the tuft-like appearance found in shams. Importantly, EPO+MLT treatment prevented the damage and restored the tuft-like appearance of EMC in CAM-IVH rats. Thus, these results demonstrate neonatal EPO+MLT treatment can modulate structural damage to EMC after CAM-IVH.

![Scanning electron microscopy (SEM) images of P21 ependymal motile cilia show preservation of cilia following EPO+MLT treatment in CAM-IVH rats. **(A)** Low magnification images demonstrate a sheet of tuft-like morphology in sham-veh rats that is disrupted in vehicle-treated CAM-IVH rats. CAM-IVH rats with EPO+MLT treatment exhibit preservation of the sheet of tufts of motile cilia. Bar = 10 microns. **(B)** Higher magnification images reveal some motile cilia in vehicle-treated CAM-IVH rats are missing. Bar = 10 microns. **(C)** High magnification images show the residual cilia appear bloated and matted in vehicle-treated rats, unlike the thinner, more upright cilia organized in tufts in sham-veh rats or EPO+MLT-treated CAM-IVH rats. Bar = 2 microns.](fncel-12-00322-g006){#F6}

EPO+MLT Prevented Low Yes-Associated Protein (YAP) mRNA Levels at P15
---------------------------------------------------------------------

Next, we tested whether EPO+MLT treatment impacted YAP mRNA transcription levels in micro-dissected ependyma at P15. Reduction of YAP mRNA levels occurred in vehicle-treated CAM-IVH rats (*n* = 4), compared to shams (*n* = 7, *p* ≤ 0.001, **Figure [7A](#F7){ref-type="fig"}**). Neonatal EPO+MLT treatment following CAM-IVH (*n* = 5) mitigated loss of YAP mRNA, compared to vehicle treated CAM-IVH (two-way ANOVA with Bonferroni correction, *p* = 0.036). These results provide initial support for our hypothesis that CAM-IVH reduces YAP transcription, and that EPO+MLT treatment prevents loss of YAP mRNA.

![Neonatal EPO+MLT treatment in CAM-IVH rats improves periventricular yes-associated protein (YAP) mRNA levels and reduces GFAP-expression. **(A)** At P15, periventricular YAP mRNA levels are reduced in micro-dissected ependyma from vehicle-treated CAM-IVH rats, compared to shams. This loss is partially, but significantly, prevented in CAM-IVH rats following EPO+MLT treatment. **(B)** GFAP-immunolabeling of coronal sections of the lateral ventricle show the choroid plexus appears shrunken in the large ventricle. EPO-MLT-treatment prevents this appearance of the choroid plexus. **(C)** Minimal GFAP-immunolabeling is present in the normal caliber third ventricle of a sham rat, while marked GFAP expression is present in the ependymal lining of the dilated third ventricle in a vehicle-treated CAM-IVH rat. In an EPO+MLT-treated CAM-IVH rat with mild ventriculomegaly, there is less GFAP present, and this pattern is more apparent in the EPO+MLT-treated CAM-IVH rat with a normal sized third ventricle (Bars = 100 microns, two-way ANOVA with Bonferroni's correction, ^∗^*p* \< 0.05, ^∗∗∗^*p* ≤ 0.001).](fncel-12-00322-g007){#F7}

EPO+MLT Treatment Reduced Excess Ependymal GFAP Expression
----------------------------------------------------------

To determine whether CAM-IVH substantially altered periventricular gliosis, P21 coronal sections were immunolabeled with GFAP (glial fibrillary acidic protein) antibodies. In the lateral ventricle, GFAP-immunolabeling in vehicle-treated CAM-IVH rats differed from shams, and demonstrated changes in both the ependyma and choroid plexus (**Figure [7B](#F7){ref-type="fig"}**). After EPO+MLT treatment, the ependyma showed less GFAP+ reactivity, and the choroid plexus resembled the choroid plexus of shams. Ependymal changes were more dramatic in the third ventricle (**Figure [7C](#F7){ref-type="fig"}**), consistent with a diffuse ependymal reaction after CAM-IVH. Sham rats showed no enlargement of the third ventricle, and minimal GFAP+ cells in the ependymal lining (**Figure [7C](#F7){ref-type="fig"}**). By contrast, ependyma in vehicle-treated CAM-IVH rats with severe ventriculomegaly exhibited dense GFAP+ expression, consistent with ventricular disruption observed in human infants with IVH ([@B76]). GFAP-immunolabeling was moderate in EPO+MLT-treated CAM-IVH rats with residual mild ventriculomegaly, while EPO+MLT-treated rats with normal ventricular size had minimal GFAP-immunolabeling, similar to shams. Notably, in this age-appropriate CAM-IVH model, the degree of GFAP expression appeared to vary inversely with ventriculomegaly.

Discussion
==========

We developed a clinically relevant model of PHHP that exhibits essential components of PHHP, progressive macrocephaly with ventriculomegaly, and used this model to test whether extended EPO+MLT treatment can prevent the development of PHHP. We found that EPO+MLT prevented progressive macrocephaly and impaired cliff aversion performance, and reduced ventriculomegaly. Neonatal EPO+MLT treatment also normalized damage from CAM-IVH to microstructural integrity of white and gray matter, ultrastructural injury to EMC, periventricular YAP levels, and ependymal GFAP-immunolabeling. These data indicate that the combination of inflammation from prenatal CAM plus early postnatal IVH damages EMC, likely limiting propulsion of CSF and leading to symptomatic PHHP. The well-characterized prenatal injury model of CAM used here causes pathological and functional changes that mimic consequences of CNS injury from extremely preterm birth ([@B48], [@B47]; [@B72]). In juvenile rats, prenatal CAM produces a gait deficit reminiscent of the spastic gait of cerebral palsy ([@B48]), and impaired executive function, social interaction and hyperactivity ([@B47]). Importantly, because of the staggered timing of CNS development and birth in rats compared to humans \[birth in Sprague-Dawley rats is equivalent approximately to 30 weeks gestation in humans, and P7-P10 in the rat is equivalent to a term human ([@B107]; [@B53])\], newborn rats mimic early preterm neonates and allow age-appropriate testing of interventions. This novel model of PHHP mimics the prenatal impact of CAM and intrauterine inflammation on CNS maturation, plus replicates the timing of IVH in early preterm infants by injecting lysed RBCs on P1. Pups exposed to prenatal CAM-IVH developed persistent ventriculomegaly with progressive macrocephaly, two hallmarks of PHHP, accompanied by histological, functional and imaging findings consistent with those observed in preterm infants with PHHP. EMC in CAM-IVH rats exhibited damage, similar to damaged EMC observed after intracerebral hematoma and TBI in the mature CNS ([@B125]; [@B18]). The combination of macrocephaly with ventriculomegaly reported here is also similar to the morphology of models of symptomatic hydrocephalus resulting from genetic mutations that impede EMC development and/or function ([@B9]; [@B115]; [@B131]; [@B92]; [@B117]; [@B91]; [@B83]; [@B85]; [@B113]; [@B1]; [@B126]). Together, the unique combination of CAM plus IVH, along with the age-appropriate timing of both insults, increases the clinical relevance of this novel model.

We used this PHHP model to test whether systemic, extended high-dose neonatal treatment with EPO+MLT could promote recovery and prevent hydrocephalus. PHHP results from a complex pattern of cumulative insults over the perinatal period, and extended dosing with EPO+MLT likely normalizes the microenvironment and enhances recovery over a sustained critical neurodevelopmental window. Preterm infants have different clinical risks of CNS damage, arising from varying patterns of IVH distribution and severity, plus other forms of neonatal injury such as periventricular leukomalacia and sepsis, and the genetic predisposition that impacts the response to these cumulative insults. The extended dosing period and combinatorial therapies likely addresses the varying severity, timing and individual predisposition to damage better than using a single agent over the developmental window. Also, CAM and IVH both affect multiple cell types in widespread CNS regions, a complex amalgam that has been identified in other forms of CNS injury from preterm birth ([@B119]). This diffuse, complex, cumulative pattern of injury sustained over several weeks by preterm infants differs substantially from a regionally and temporally specific injury such as a single occlusive middle cerebral artery stroke. EPO and MLT also have numerous overlapping complementary mechanisms of action on neural cells that result in repair ([@B12]; [@B15]). Receptors for both EPO and MLT are present on neural cells ([@B73]; [@B8]; [@B84]; [@B89]; [@B116]), and both EPO and MLT enhance the genesis, survival and maturation of multiple neural cell types ([@B46]; [@B73]; [@B52]; [@B68]; [@B132]). EPO and MLT reduce neuroinflammation and oxidative stress ([@B14]; [@B95]; [@B24]; [@B77]; [@B120]; [@B122]; [@B135]). They also restore the microenvironment by limiting excess calpain activity that promotes cell death and destroys molecules essential for neurodevelopment ([@B104]; [@B49], [@B54]; [@B99]). EPO and MLT reduce endoplasmic reticulum stress and mitochondrial dysfunction that may propagate chronic damage and precipitate early neurodegeneration ([@B42]; [@B21]; [@B13]; [@B30]; [@B38]; [@B134]; [@B44]; [@B39]; [@B78]; [@B127]). Additionally, EPO+MLT treatment likely suppresses LPA, increases YAP, and enhances ependymal renewal, which when combined with white matter repair, provides a unique advantage to stimulate recovery from the cascade of insults the cumulatively lead to PHHP. Further work to delineate the specific mechanisms of how EPO and MLT act together to optimize EMC maturation following CAM-IVH are underway.

Systemic inflammation, particularly from maternal causes, is associated with a higher risk of IVH ([@B80]; [@B103]; [@B6]; [@B108]; [@B65]; [@B69]; [@B111]; [@B19]; [@B25]). The Gram-negative endotoxin LPS used here binds TLR4 (toll-like receptor 4), a receptor implicated in neonatal parenchymal microhemorrhages ([@B17]). Others have also shown that a TLR4 antagonist limits damage from intracerebral hemorrhage ([@B121]; [@B62]). Systemic inflammation mediated via TLR4 increases choroid plexus CSF secretion ([@B58]), and likely contributes to ventriculomegaly in hydrocephalus. We found that EPO+MLT treatment not only limited ependymal GFAP-expression, but also prevented altered morphology of the choroid plexus. Thus, there are multiple potential mechanisms to explain why this combinatorial therapy limits the development of PHHP.

We used this novel PHHP model to test the potential reversibility of ependymal injury. Based on prior work ([@B131]; [@B45]; [@B91]), we reasoned that one potential explanation connecting systemic inflammation to the propensity to develop PHHP after IVH is that systemic inflammation from LPS impacts ependymal cells, and potentially neural cell progenitor differentiation, through alterations in periventricular YAP mRNA levels. Here we report that CAM-IVH reduces YAP transcription in micro-dissected ependyma, and that neonatal EPO+MLT prevents loss of YAP mRNA. These data are consistent with a role for YAP in the mitigation of EMC damage, as observed with SEM in this report.

Studies using DTI in children with hydrocephalus have shown alterations in white matter microstructural integrity ([@B71]; [@B133]), similar to what we have shown here in toddler-equivalent P21 vehicle-treated CAM-IVH rats. In preclinical studies, extended neonatal EPO treatment mitigated widespread DTI abnormalities in white and gray matter ([@B99], [@B98]). Here, we showed that sustained neonatal treatment with EPO+MLT normalizes subacute DTI changes at 3 weeks after CAM-IVH. To our knowledge, this is the first report of the prevention of DTI microstructural damage in a preclinical model of PHHP. [@B5] used the transforming growth factors-β antagonist decorin to prevent DTI changes at 2 weeks in a kaolin model of hydrocephalus. Similarly, neonatal kaolin resulted in DTI abnormalities at 5 and 10 days ([@B130]). The DTI analyses here demonstrated that both white matter and gray matter, and particularly the corpus callosum, are sensitive to CAM-IVH. While a component of white matter vulnerability may be related to direct structural injury from ventriculomegaly, it is likely that myelination and EMC function are precise, highly regulated, relatively vulnerable processes with demanding energy expenditures and environmental requirements. We reasoned that the precise regulation of EMC maturation and function, as well as recovery of more widespread injury to white and gray matter after CAM-IVH, required a potent, multipronged intervention. This led us to test a neonatal, sustained, high-dose, neuroprotective, clinically relevant dosing regimen of EPO+MLT.

While clinical studies have shown that isolated neonatal symptomatic hydrocephalus does not cause chronic neurological deficits ([@B94]), children with PHHP often suffer from additional neurological co-morbidities such as cerebral palsy, behavioral abnormalities and impaired cognition. Prenatal inflammation plus postnatal inflammation increases the risk of white matter injury and spastic cerebral palsy ([@B128]), and many preterm infants with IVH suffer from neonatal inflammation that likely contributes to their poor functional outcomes. A sustained EPO+MLT regimen, similar to the one used here, prevents chronic motor, social, behavioral and cognitive deficits in adult rats following prenatal CAM ([@B47]). In this study EPO+MLT treatment prevented poor performance on cliff aversion, however, tests of neonatal function in rodents are inherently limited. Using a strategy similar to EPO+MLT to induce multi-faceted repair, intravenous or intraventricular injection of umbilical-cord derived mesenchymal stromal cells on P6 improved early functional outcomes and reduced ventriculomegaly and GFAP-expression in rats with IVH on P4 or P5 ([@B3]; [@B82]). Repetitive dosing with EPO+MLT has the distinct advantages of providing sustained stabilization of the microenvironment over extended perinatal course, known safety profile, ease of administration, and cost. Early intervention for ventriculomegaly from IVH may improve long term cognition in very selected populations ([@B66]), yet preterm infants with two or more surgeries as neonates have lower cognitive scores ([@B33]), and shunt surgery at a young age increases the risk of shunt malfunction ([@B96]). While the timing of interventions for sick preterm infants with PHHP is a complex and evolving controversy, non-surgical intervention such as neonatal EPO+MLT could potentially minimize the need for more invasive procedures and their associated risks.

The pathogenesis of PHHP is likely similar to other types of acquired hydrocephalus from TBI, adult IVH, subarachnoid hemorrhage, or meningitis. The association between CNS inflammation and hydrocephalus is well known ([@B22]). More recently the association with systemic inflammation has been found. Sepsis increases the risk of developing hydrocephalus in infants and young children with TBI ([@B101]). Similarly, [@B123] showed that sustained systemic inflammatory response syndrome (SIRS) increases the risk of developing shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage. Adults with severe TBI are more likely to need surgical treatment for hydrocephalus in the presence of ventriculitis/meningitis ([@B10]; [@B43]). Interestingly, after adult stroke in a preclinical model, increased GFAP expression was found in the ependymal lining, and EMC were affected, but hydrocephalus did not develop ([@B129]). Numerous differences in the manifestations of injury and potential for repair exist between the developing and mature CNS. Current preclinical experiments are underway to determine whether findings from this study are relevant to acquired hydrocephalus in adults.

This study has several limitations. Many important mechanistic questions are beyond the scope of this initial report. Additional experiments are needed to clarify the limits on the timing and extent of renewal of ependymal cells and EMC, and thus the duration of the optimal dosing regimen. While the results presented here support our hypothesis that EMC damage in the neonatal period can be modulated significantly by endogenous neuroprotective agents, the situation in human neonates with PHHP is likely more complex. More specifically targeted therapies may add benefit, particularly in vulnerable patients due to their genetic or epigenetic risk factors. Still, the findings presented here suggest that neonatal EPO+MLT may offer a safe, effective, cost-sensitive treatment for at least a subset of infants with PHHP. Additional studies are underway to test cognitive outcomes in young adult rats after CAM-IVH. This is exceedingly important as children with ventricular dilatation after IVH of prematurity have cognitive deficits ([@B41]), and those who require surgical intervention are at even higher risk for poor outcomes ([@B2]; [@B41]). Elevated LPA levels from systemic inflammation may reduce YAP transcription and its specification of radial glial cells to differentiate into ependymal cells, however, investigation of this hypothesis requires additional studies to clarify the timing of damage, and therapeutic window for repair. Our initial findings suggest that ventriculomegaly in this model is associated with diffuse ependymal GFAP+ reaction, however, any potential causal relationship is currently unknown. Experiments to evaluate the long term impact of CAM-IVH and the association with macrocephaly and ventriculomegaly are underway. Moreover, while we demonstrated that both sexes develop progressive macrocephaly, the study was not sufficiently powered to determine how well each sex responds to EPO+MLT treatment. Despite these and other limitations, this novel model of PHHP and our initial findings using the clinically viable EPO+MLT treatment to prevent macrocephaly with ventriculomegaly, poor cliff aversion performance and associated microstructural abnormalities warrants additional investigation.

Conclusion
==========

In conclusion, early preterm birth and its associated complications, including IVH and PHHP, remain a serious global challenge to infant and childhood mortality and morbidity. The findings reported here address several of the needs identified in a recent NIH-sponsored symposium on hydrocephalus ([@B75]). The age-appropriate, clinically relevant model of PHHP induced by prenatal CAM plus P1 IVH provides a means to test mechanisms and potential interventions to modulate hydrocephalus in neonates. Our results support the use of DTI as an imaging biomarker of injury and repair for PHHP. Most importantly, use of a clinically viable regimen of endogenous neuroprotective agents EPO and MLT to prevent PHHP suggests that safe, economically sound, non-surgical treatments for hydrocephalus may be possible to transform the care of preterm infants with severe IVH in the near future.
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###### 

Both male and female rats exhibit similar patterns of progressive macrocephaly and poor cliff performance after CAM-IVH, and respond similarly to EPO+MLT treatment. **(A)** Male CAM-IVH rats (*n* = 10) show significant macrocephaly from P10 through P21, compared to sham-veh (*n* = 17), sham-IVH (*n* = 9), and CAM-veh (*n* = 10) rats. **(B)** Similarly, female CAM-IVH rats (*n* = 12) have larger IADs compared to sham-veh (*n* = 16), sham-IVH (*n* = 11), and CAM-veh rats (*n* = 9). **(C)** Neonatal EPO+MLT treatment prevents progressive macrocephaly in male CAM-IVH rats (*n* = 9), compared to vehicle-treated CAM-IVH rats (*n* = 13). By P21, IADs of male EPO+MLT-treated rats are similar to male shams (*n* = 15). **(D)** Similarly, the IADs of female EPO+MLT-treated rats (*n* = 6) match female shams (*n* = 13), and diverge from female vehicle-treated CAM-IVH rats (*n* = 15). **(E)** For cliff aversion, male CAM-IVH rats (*n* = 14) perform worse than sham-veh rats (*n* = 12) and sham-IVH rats (*n* = 8), while CAM-veh rats (*n* = 17) also perform poorly. **(F)** Female CAM-veh (*n* = 10) and CAM-IVH rats (*n* = 14) show a similar pattern, compared to sham-veh (*n* = 12) and sham-IVH (*n* = 10) rats, but the differences are not statistically significant. **(G)** Male vehicle-treated CAM-IVH rats (*n* = 14) perform poorly on cliff aversion compared to sham-veh rats (*n* = 12) and EPO+MLT--treated CAM-IVH rats (*n* = 8). **(H)** While the trend for female vehicle-treated CAM-IVH rats (*n* = 10) compared to sham-veh (*n* = 12) and EPO+MLT-treated CAM-IVH rats (*n* = 9) is similar to the male rats, the differences are not statistically significant. **(I)** To test the efficacy of EPO alone or MLT alone, CAM-IVH littermates were treated with vehicle (*n* = 8), EPO alone (*n* = 9), MLT alone (*n* = 5), or EPO+MLT (*n* = 8), and compared to vehicle-treated CAM-veh rats (*n* = 13). P21 IADs of EPO-treated or MLT-treated CAM-IVH rats were not different than vehicle-treated CAM-IVH rats. By contrast, IADs of EPO+MLT-treated CAM-IVH rats were different than vehicle-treated CAM-IVH rats, and were similar to the CAM-veh controls. (Comparisons are **A--D**: a mixed model repeated measures ANOVA; **E--I**: two-way ANOVA with Bonferroni's correction, ^∗^*p* \< 0.05, ^∗∗^*p* ≤ 0.01, ^∗∗∗^*p* ≤ 0.001.)

###### 

Click here for additional data file.

###### 

Neurobehavioral tests in neonatal rats are minimally affected by CAM-IVH. **(A)** Surface righting, the sum of the time to turn from lying on the back to upright on feet during three trials from P7 to P9, was mildly impaired in CAM-IVH rats compared to sham-veh rats, but the difference was not significant. The negative geotaxis (**B**, sum of time to redirect when placed on an inclined plane from pointing head down, with maximum of 30 s), the presence of forelimb grasp on P8 **(C)**, the presence of audio startle on P13 **(D)**, the presence of eye opening on P14 **(E)**, and the presence of ear twitch to cotton wisp on P14 **(F)** all did not differ between groups. **(G)** The presence of forelimb placement to stimulus on the dorsum of the forelimb on P15 was reduced in injured rats. **(H)** The ability to turn upright after being dropped upside down above a cushioned surface on P12 did not differ between groups. **(I)** Surface righting improved mildly in EPO+MLT-treated CAM-IVH rats compared to vehicle-treated CAM = IVH rats, but the trend was not significant. **(J--P)** None of the other reflexes differed significantly between the vehicle and EPO+MLT-treated CAM-IVH rats \[*n* = 16--31, two-way ANOVA with Bonferroni correction **(A,B,I,J)** or Kruskal--Wallis with Dunn's *post hoc* correction **(C--H,K--P)**\]. ^∗^*p* \< 0.05, ^∗∗∗^*p* \< 0.001.

###### 

Click here for additional data file.

###### 

Neurodevelopment was assessed in naïve rats treated with EPO+MLT (*n* = 20) or vehicle (*n* = 10). Surface righting on P5--P7 **(A)**, negative geotaxis on P8--P14 **(B)**, cliff aversion on P12--P13 **(C)**, forelimb grasp on P10--P11 **(D)**, ear twitch on P14 **(E)**, forelimb placement on P15 **(F)**, and air righting on P12 **(G)** did not differ between vehicle-treated and EPO+MLT-treated naïve rats.

###### 

Click here for additional data file.
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